Login to Your Account

Clinic Roundup

Monday, May 9, 2011
Cephalon Inc., of Frazer, Pa., presented results from a Phase IV trial of Nuvigil (armodafinil) tablets [C-IV] with 383 people with excessive sleepiness associated with shift work disorder that showed improvement in the shift-workers' overall clinical condition late in their shifts (i.e., 4 a.m. to 8 a.m.), including the commute home, compared to placebo. Results were presented at the Society of General Internal Medicine's 34th Annual Meeting in Phoenix.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription